āshibio, a privately held clinical-stage biotechnology company based in Burlingame, California, has reported preliminary efficacy findings from the Phase 2/3 ANDECAL programme showing an 86.2% reduction in the rate of new flare-ups among patients with fibrodysplasia ossificans progressiva (FOP) receiving andecaliximab at a dose of 300 mg weekly. Announced on October 13, 2026, following a presentation at the American Society for Bone and Mineral Research Annual Meeting in Boston, the findings provide an initial human efficacy signal for the investigational antibody targeting matrix metalloproteinase-9 (MMP9).
The result emerged from ANDECAL-1, the 12-participant safety, dose-finding and preliminary efficacy component of a larger Phase 2/3 clinical programme. The reported reduction was calculated against flare-up activity during the six months preceding baseline rather than against a concurrently randomized placebo group. Consequently, the magnitude of the observed decline cannot yet establish how much of the improvement was caused by andecaliximab rather than variation in disease activity or other influences.
The announcement also disclosed that ANDECAL-1 enrolled patients with relatively active disease. Eleven of the 12 participants carried the R206H variant of the ACVR1 gene, while all participants had experienced new or ongoing flare-ups within approximately two and a half months before entering the study. The company is pursuing MMP9 inhibition as a strategy to intervene in the inflammatory processes associated with abnormal bone formation.
The findings arrive during a rapidly changing period for FOP treatment, following three United States Food and Drug Administration approvals since 2023, including two in August and September 2026. For āshibio, the central development question is whether the reduction in flare-ups observed during the initial study can be reproduced against placebo and accompanied by measurable prevention of heterotopic ossification, the progressive formation of bone in muscles and other soft tissues.
How should the 86.2% reduction in FOP flare-ups be interpreted clinically?
The headline figure is the most important efficacy signal disclosed by āshibio, but its interpretation depends on the comparison used. The company reported an 86.2% reduction in the rate of new flare-ups at the 300 mg weekly dose relative to the six months before treatment began. It did not disclose the underlying flare-up counts, the number of participants contributing to this dose-specific analysis, confidence intervals or a statistical significance value.
ANDECAL-1 was designed primarily to investigate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy, rather than provide definitive proof of treatment benefit. Its participants received one of two andecaliximab dose levels during a 13-week controlled assessment period, with no placebo recipients in Part 1. Although dose assignment was blinded, every participant received active treatment, limiting the ability to distinguish drug effects from changes that might have occurred without treatment.
The characteristics of the enrolled population create an additional consideration. āshibio reported that 92% of participants had experienced at least one new flare-up during the 12 months before baseline, compared with 66.7% in a historical FOP natural history study. The average number of new flare-ups was 3.25 per participant in ANDECAL-1, compared with 2.5 among natural history participants.
Patients recruited during periods of unusually high disease activity may experience fewer episodes later, even without an effective intervention. This phenomenon, commonly described as regression toward the mean, is particularly relevant when comparing a treatment period with a preceding interval selected partly because of frequent symptoms. The reported reduction is encouraging, but a placebo-controlled comparison will be necessary to determine the treatment-attributable effect.
Why is MMP9 inhibition a different therapeutic approach to preventing abnormal bone formation in FOP?
Fibrodysplasia ossificans progressiva is an ultra-rare genetic disorder in which bone progressively forms outside the normal skeleton, including within muscles, tendons, ligaments and other connective tissues. Most affected individuals carry an activating mutation in the ACVR1 gene, which encodes the ALK2 receptor involved in bone formation signalling. The R206H variant is the most common disease-causing alteration and was present in 11 of the 12 ANDECAL-1 participants.
The abnormal receptor activity contributes to heterotopic ossification, particularly following inflammatory episodes, tissue injury or other triggers. Over time, the accumulation of extra-skeletal bone can restrict movement, permanently immobilize joints and interfere with essential functions such as eating, walking and breathing. Preventing new bone formation is therefore a central objective of disease-modifying treatment development.
Andecaliximab takes an indirect approach by inhibiting MMP9, an enzyme involved in modifying the extracellular matrix and regulating inflammatory signalling. Rather than blocking the mutant ALK2 receptor directly, the antibody is intended to interfere with upstream processes that can facilitate the release and activity of molecules involved in abnormal bone formation.
The scientific rationale emerged partly from research involving a man carrying the characteristic FOP-causing mutation who nevertheless exhibited unusually limited heterotopic ossification and preserved mobility. Investigators identified genetic alterations associated with reduced MMP9 activity, prompting experiments to determine whether this pathway could influence disease severity. Subsequent research published in the Journal of Bone and Mineral Research in 2024 found that genetic or pharmacological MMP9 inhibition substantially reduced injury-induced abnormal bone formation in several FOP mouse models.
Those experiments suggested that MMP9 contributes to the availability of Activin A and other biological signals within injured tissues. Activin A has an established role in triggering abnormal bone formation through the mutant ACVR1 pathway. Blocking MMP9 could therefore reduce the inflammatory and molecular conditions that favour heterotopic ossification, although the magnitude of this effect in humans has not yet been established.
The approach is scientifically differentiated because it targets processes associated with inflammation and tissue remodelling rather than the central disease-causing receptor alone. Whether that distinction translates into a meaningful clinical advantage will depend on the ability to reduce new bone formation without disrupting normal tissue repair.
Does reducing FOP flare-ups establish that andecaliximab can prevent permanent disability?
One important limitation of the latest findings is the difference between reducing symptomatic flare-ups and preventing new heterotopic bone lesions. FOP flare-ups can involve painful swelling, warmth, stiffness and restricted movement, and they frequently accompany the development of abnormal bone. However, not every flare-up necessarily leads to measurable new bone formation, while heterotopic ossification can also develop without a clearly recognized flare-up.
The ANDECAL-1 announcement concentrated on flare-up frequency and baseline disease characteristics. It did not provide a quantified reduction in new heterotopic ossification lesions, total new bone volume or long-term functional deterioration. Consequently, the 86.2% reduction should not be described as an equivalent reduction in abnormal bone formation or disability risk.
The distinction is clinically consequential because patients ultimately need therapies that preserve mobility and reduce the accumulation of irreversible skeletal restrictions. Fewer painful episodes would be valuable, but preventing new bone formation could have additional implications for long-term function and independence. Establishing both outcomes would provide a stronger basis for evaluating the disease-modifying potential of MMP9 inhibition.
Future analyses will therefore need to examine whether changes in flare-up rates correspond with objectively measured changes in heterotopic ossification. Whole-body computed tomography can identify newly formed bone lesions, while functional assessments provide information about joint restriction and disease progression. These measurements will be important for determining whether the early symptomatic signal translates into sustained clinical benefit.
How will the randomized Phase 2/3 ANDECAL study test andecaliximab against placebo?
The ANDECAL programme, registered as NCT06508021, is a global, multicentre Phase 2/3 investigation designed to assess andecaliximab in children and adults with FOP. The programme has an estimated total enrolment of approximately 92 participants, including the 12-person lead-in component and a main study planned for approximately 80 participants. The public trial record identifies the investigation as active but not currently recruiting.
The main study is designed to randomize participants between two andecaliximab dose levels and placebo in a 1:1:1 allocation. Treatment is administered through weekly subcutaneous injections during a 52-week double-blind period. Participants may subsequently enter an open-label extension in which active treatment is available, providing an opportunity to collect longer-term safety and efficacy information.
A central efficacy measure is the number of new heterotopic ossification lesions detected through whole-body computed tomography, excluding the head, at specified assessments during the study. Additional measures include changes in abnormal bone volume, flare-up incidence, symptoms and patient-reported outcomes. The longer controlled observation period is intended to address questions that cannot be resolved through the short lead-in study.
The study also provides a framework for evaluating andecaliximab across different ages. Initial participation focused on adolescents and adults, with provisions to include younger children through protocol-defined age step-down procedures after appropriate safety assessments. Such an approach is relevant because FOP frequently begins during childhood, but evidence obtained in adults cannot automatically establish an acceptable benefit-risk profile in younger patients.
The controlled comparison should help determine whether reduced flare-up frequency is accompanied by fewer new bone lesions and improved functional outcomes. It will also provide more reliable information about the effect of different doses and the frequency of adverse events. The October announcement did not provide a confirmed date for the main study’s primary results.
What does previous andecaliximab research reveal about safety and tolerability?
Andecaliximab is not a newly discovered antibody entering human testing for the first time. It has previously been evaluated in approximately 1,000 participants across clinical programmes involving cancer and inflammatory conditions, providing a larger historical safety database than many early-stage rare disease candidates. However, those studies involved different patient populations, treatment regimens and clinical circumstances.
A pooled analysis presented at the 2024 American Society for Bone and Mineral Research meeting examined 347 participants from earlier subcutaneous andecaliximab studies. Treatment-related adverse events occurring at least one percentage point more frequently with the antibody than placebo included injection-site erythema, reported in 2.1% versus 1.1%, and headache, reported in 1.4% versus none. Anemia and injection-site pain were each reported in 1.1% of antibody recipients compared with none receiving placebo.
These findings provide useful background for dose selection and initial safety planning, but they cannot establish long-term tolerability in people with FOP. Patients with this disease may have substantial mobility restrictions and complex physical vulnerabilities, including difficulties involving respiratory function and the consequences of existing heterotopic bone. The safety implications of prolonged MMP9 inhibition will also need to be examined within the context of normal inflammatory responses and tissue repair.
The October 13 release did not provide a detailed adverse-event table specifically for the 12 ANDECAL-1 participants. Nor did it disclose comprehensive dose-specific safety findings, treatment discontinuations or immunogenicity results from the FOP population. These omissions limit the extent to which the lead-in study can be evaluated independently.
āshibio Chief Executive Officer Pankaj Bhargava characterized the preliminary findings as encouraging and highlighted the company’s confidence in MMP9 as a therapeutic target. His assessment reflects the scientific rationale for continued development, while the eventual safety conclusions will depend on the complete FOP-specific clinical dataset.
How does andecaliximab compare with the three FDA-approved treatments now available for FOP?
The competitive environment has changed substantially since the ANDECAL programme began in October 2024. As of October 13, 2026, the FDA has approved three treatments for FOP, each addressing abnormal bone formation through a different therapeutic mechanism or regulatory indication. Andecaliximab would therefore enter an increasingly established treatment field if its development ultimately succeeds.
Ipsen’s Sohonos (palovarotene), approved in August 2023, was the first FDA-authorized treatment for FOP. The oral retinoid is indicated to reduce new heterotopic ossification volume in adults and in children aged eight years and older for females and ten years and older for males. Its prescribing information includes important safety considerations involving embryo-fetal toxicity and growth-related effects in pediatric patients.
Regeneron Pharmaceuticals’ Pasatru (garetosmab-grts) received FDA approval on August 19, 2026, to reduce new heterotopic ossification lesions and clinician-assessed flare-ups in adults with FOP. The antibody blocks Activin A, a signalling protein involved in abnormal bone formation, and is administered through intravenous infusion every four weeks. Its randomized Phase 3 OPTIMA trial provided controlled evidence supporting the approved indication.
Regeneron reported additional 84-week OPTIMA findings on October 12, 2026, showing sustained control of new heterotopic ossification lesions and reduced clinician-assessed flare-ups during extended follow-up. Those findings strengthen the evidence available for an already approved competitor. They also establish a more demanding evidentiary environment for investigational medicines seeking a place in the treatment landscape.
A third option entered the market on September 25, when the FDA approved Mirum Pharmaceuticals’ Atebrioz (zilurgisertib) for reducing the volume of total new heterotopic ossification in adults and children aged 12 years and older. The once-daily oral medicine inhibits ALK2, addressing the disease-driving signalling pathway more directly.
Andecaliximab’s proposed differentiation lies in targeting MMP9 and the inflammatory processes associated with heterotopic ossification. However, the available 86.2% flare-up reduction cannot be compared directly with efficacy percentages reported for the approved medicines because the trials used different designs, populations, treatment periods and endpoints. āshibio will need placebo-controlled evidence of new bone lesion reduction and an acceptable safety profile before meaningful conclusions about its competitive position can be drawn.
Could andecaliximab development extend beyond FOP into more common forms of abnormal bone formation?
āshibio is also investigating andecaliximab for non-hereditary heterotopic ossification, a condition that can arise following spinal cord injury, traumatic brain injury, major orthopedic surgery, burns or other forms of tissue damage. Unlike FOP, these cases generally occur without the inherited ACVR1 mutation responsible for the rare genetic disorder. Nevertheless, inflammation and abnormal tissue repair are relevant to both forms of ectopic bone formation.
The company believes that MMP9 inhibition could have therapeutic potential across these conditions because the enzyme participates in processes involving inflammation and extracellular matrix remodelling. Its broader development programme includes clinical investigation involving people with spinal cord injury who are at risk of developing heterotopic ossification. The October FOP findings provide additional support for studying the pathway but do not establish effectiveness in non-hereditary disease.
The potential market is substantially broader than FOP. āshibio estimates that non-hereditary heterotopic ossification affects approximately 100,000 patients across the United States, Europe and Japan, although this is a company-reported population estimate rather than a confirmed addressable commercial market. Clinical eligibility would depend on the precise cause of abnormal bone formation, treatment timing and eventual evidence supporting a particular indication.
The expansion opportunity also creates important development questions. A therapy intended to prevent bone formation following spinal cord injury may require different timing, duration and endpoints from a treatment intended for lifelong genetic FOP. Human evidence generated in one condition would not independently establish the benefit-risk profile in the other.
The company’s wider pipeline includes vantictumab, an investigational antibody being developed for autosomal dominant osteopetrosis type 2, a condition involving impaired bone resorption. āshibio has indicated plans to move that programme into clinical development in the first half of 2028. The portfolio reflects a broader focus on rare bone disorders, although andecaliximab remains its most advanced clinical asset.
What will determine whether andecaliximab becomes a viable treatment for FOP?
The immediate scientific priority is to establish whether the preliminary reduction in flare-up frequency can be reproduced in a randomized population. ANDECAL-1 provides a potentially important signal because all 12 participants entered the programme with recent disease activity and the 300 mg weekly dose was associated with a substantial decline in new flare-ups. However, the absence of a concurrent placebo comparison prevents the observed difference from being interpreted as a confirmed treatment effect.
The larger ANDECAL study is designed to answer a more consequential question: whether MMP9 inhibition prevents the development of new heterotopic ossification lesions over a meaningful treatment period. Demonstrating that effect would provide stronger evidence of disease modification than flare-up reduction alone. Longitudinal safety findings, functional assessments and results in younger patients will also influence the programme’s future development requirements.
Commercially, āshibio faces a more competitive environment following the recent approvals of Pasatru and Atebrioz. The company is privately held and has not disclosed development-specific revenue projections or a commercialization timetable for andecaliximab. Its eventual opportunity will depend on clinical differentiation, regulatory authorization, access arrangements and whether its mechanism offers benefits for patients not adequately served by existing therapies.
The newly disclosed ASBMR findings strengthen the rationale for investigating MMP9 as a therapeutic target in fibrodysplasia ossificans progressiva, building on previous laboratory research and the antibody’s historical human safety experience. They do not yet prove that andecaliximab prevents abnormal bone formation, preserves mobility or offers superior outcomes to currently approved medicines. The next decisive evidence will come from the controlled ANDECAL programme, where changes in objectively measured heterotopic ossification and FOP-specific safety will determine whether the early flare-up signal can translate into a credible treatment benefit.
